One Article About Big Pharma, Two Hot Takes


Being at the intersection of health care and patents, two subjects that concern myself personally, I found this story interesting. Basically, Humira is being priced into the stratosphere in the U.S. because of a combination of patent leveraging and the inability of Medicare to negotiate pricing, resulting in sob stories of people who need the drug and not being able to afford it.

I had two takes on it, the patent take and the health care take, posted at two different places. I’ve made it easy for you by putting both here together.